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Background: High on-treatment platelet reactivity (HTPR) has been reportedly associated with adverse ischemic events after coronary intervention. 
A recent study showed “thrombo-restenosis” pattern in restenotic lesions after coronary stent implantation by using optical coherence tomography. 
However, an association between HTPR and restenosis has not been fully elucidated. Therefore, this study was designed to determine whether HTPR 
correlates with in-stent restenosis after coronary stent implantation in patients with stable angina. 
methods: The study group consisted of 79 patients (mean age 68.8±10.8 years, 81 coronary lesions) with the following characteristics: chronic 
stable angina, receiving chronic dual anti-platelet agents (100mg of aspirin and 75mg of clopidogrel) and elective and successful coronary artery 
stenting. Platelet reactivity was determined by arachidonic acid (AA) and adenosine diphosphate (ADP) -induced platelet aggregation (PA) of whole 
blood samples using multiple electrode aggregometry before stenting. HTPR was defined as both the AA-PA more than 17U and the ADP-PA more than 
34U. A successful stenting was defined as a residual diameter stenosis of <50%. Angiographic restenosis was defined as stenosis >50% of the lumen 
diameter measured by quantitative computerized angiography at follow-up (1-year or earlier if clinically indicated). 
results: The levels of AA-PA and ADP-PA were significantly higher in cases with restenosis (n=9) than in cases without restenosis (n=70) (18.1±8.3U 
vs. 11.0±6.1U, p=0.0024 and 43.2±16.2U vs. 31.3±13.2U, p=0.016), respectively. The incidence of restenosis was significantly higher in cases with 
HTPR (n=13) than in cases without HTPR (n= 66) (46.2% vs. 4.6%, p<0.0001). Late lumen loss was significantly higher in patients with HTPR (n=13) 
than in patients without HTPR (n=68) (0.97±0.93mm vs. 0.29±0.55mm, p=0.0007). On multivariate analysis, HTPR was the only independent 
predictor of restenosis (odds ratio=17.4, p=0.0031). Clinical characteristics of the population were similar for the two groups at baseline. 
conclusions: Our results suggested that HTPR was associated with restenosis after coronary stent implantation.
